Constellation Pharmaceuticals (Constellation Pharmaceuticals) Current Accrued Expense : $15.00 Mil (As of Mar. 2021)

View and export this data going back to 2018. Start your Free Trial

What is Constellation Pharmaceuticals Current Accrued Expense?

Constellation Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2021 was $15.00 Mil.

Constellation Pharmaceuticals's quarterly Current Accrued Expense declined from Sep. 2020 ($12.62 Mil) to Dec. 2020 ($11.17 Mil) but then increased from Dec. 2020 ($11.17 Mil) to Mar. 2021 ($15.00 Mil).

Constellation Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2018 ($5.87 Mil) to Dec. 2019 ($7.89 Mil) and increased from Dec. 2019 ($7.89 Mil) to Dec. 2020 ($11.17 Mil).

Constellation Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Constellation Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Constellation Pharmaceuticals Current Accrued Expense Chart

Constellation Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Current Accrued Expense

1.57

2.14

5.87

7.89

11.17

Constellation Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Current Accrued Expense	Get a 7-Day Free Trial													10.92	13.14	12.62	11.17	15.00

Constellation Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Constellation Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Constellation Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Constellation Pharmaceuticals (Constellation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Constellation Pharmaceuticals Inc (NAS:CNST) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 First Street, Suite 200, Cambridge, MA, USA, 02142

Website

http://www.constellationpharma.com

Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.

Executives

Emma Reeve	officer: Chief Financial Officer	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Karen Valentine	officer: See Remarks	C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421
Mark A Goldsmith	director, 10 percent owner	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Humphrey	officer: Chief Medical Officer	C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Elizabeth Trehu	director	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
James E Audia	director	215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142
Adrian Senderowicz	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jigar Raythatha	director, officer: See Remarks	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Patrick Trojer	officer: Chief Scientific Officer	215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158